Pomerantz Law Firm Investigates Journey Medical Corporation for Potential Securities Fraud
Pomerantz LLP is investigating Journey Medical Corporation (NASDAQ: DERM) for potential securities fraud following concerns raised about prescription demand for Emrosi exceeding reported revenue. The firm is seeking investors to join a class action. Journey's stock dropped 30.01% after management acknowledged issues with reimbursement and co-pay assistance programs.
Topics: class_action financial_disclosure securities_fraud stock_price_drop